1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
2.3. Data Validation
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Supplier
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) BY APPLICATION
5.1. Introduction
5.2. Diabetes Patients
5.3. Critical Patients
6. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) BY END-USER INDUSTRY
6.1. Introduction
6.2. Hospitals
6.3. Diagnostic Centers & Clinics
6.4. Home Care
7. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) BY GENDER
7.1. Introduction
7.2. Male
7.3. Female
8. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY AGE
8.1. Introduction
8.2. Greater than 20 years
8.3. Less than 20 years
9. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY TYPE
9.1. Introduction
9.2. Real-time CGM
9.3. Intermittently Scanned CGM
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Emerging Players and Market Lucrativeness
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. Abbott Laboratories
11.2. Medtronic plc
11.3. Roche Diabetes Care, Inc.
11.4. Tandem Diabetes Care, Inc.
11.5. ARKRAY Inc.
11.6. Taidoc Technology Corporation
11.7. Bionime Corporation (Ypsomed AG)
11.8. Novo Nordisk A/S